•
How I automate my expenses, savings & Investing using free phone apps
Talks about Money, Finance and Personal Finance
MH
Michael Henry
Member at Berkeley Investor Network
Berkeley, California
Overview
Michael Henry is the Chief Business Officer at Aldatu Biosciences, a leader in adaptive PCR diagnostics for global health and emerging diseases. With a background in business development and leadership roles at companies like Ancestry and Quest Diagnostics, he brings expertise in strategic planning and commercialization to drive innovation in the pharmaceutical industry.
His career highlights include serving as Vice President of Business Development at both Ancestry and Quest Diagnostics, showcasing his ability to lead successful partnerships and drive growth in the life sciences sector. Currently, as the CBO at Aldatu Biosciences, he continues to leverage his experience to advance personalized medicine and technology transfer in the biotechnology field.
Work Experience
Chief Business Officer
2020 - Current
Aldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases.
Raised $7,800,000.00 from National Institute of Allergy and Infectious Diseases, Massachusetts Life Sciences Center, National Institutes of Health and National Institutes of Health.
Member
2017
Berkeley Angel Network is a venture capital and private equity firm that specializes in the fields of finance and investment management.
Senior Vice President and General Manager, Consumer Genomics
2016 - 2018
Reporting to the CEO, led strategy, marketing, operations, new product development, financing and deal making for the consumer genomics business at Centrillion. • Negotiated a TeloYears Advanced Ancestry DNA test agreement with Telomere Diagnostics.
Vice President, Business Development
2015 - 2016
Led business development for AncestryDNA and AncestryHealth, subsidiaries of Ancestry, a $683 million 2015 revenue consumer internet company and leader in online genealogy and consumer genomics. • Sold Ancestry to Silver Lake and GIC for $2.6 billion in 2016. • Led the team that managed the longevity therapeutics target discovery collaboration with Calico, an Alphabet / Google company. • Secured a genotyping test services collaboration agreement with Quest Diagnostics.
Ancestry is a web-based platform that helps its users to create their own family tree and help them preserve and share their family history.
Raised $33,200,000.00 from Silver Lake, Spectrum Equity, GIC and Banneker Partners.
Board of Directors
2014 - 2015
Member
2014 - 2015
Launchpad Venture is an angel investment group that provides funding to early-stage companies.
Vice President, Business Development
2013 - 2014
Led business development for the General Health and Wellness franchise, a $1.8 billion 2012 revenue segment of Quest Diagnostics, a $7.2 billion 2012 revenue diagnostics laboratory. • Acquired Summit Health, a provider of on-site wellness programs for employers, health plans and retail clinics, for $113 million plus a $25 million contingent payment.
Quest Diagnostics Foundation is to promote the benefits of healthcare and wellness, as well as to promote prevention.
Vice President, Business Development
2004 - 2013
Reporting to the CEO, led business development including mergers, acquisitions, divestitures, patents, licensing, strategic planning, launching new businesses and supervision of five staff for a $110 million 2010 revenue genetic testing laboratory. • Sold Athena to Quest Diagnostics for $740 million in 2011. • Sold Athena to Fisher Scientific for $283 million in 2006. • Licensed and/or launched 271 new products during 2004-2012 achieving double digit new product sales growth.
Board of Directors
2008 - 2008
Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.
Raised $46,349,000.00 from LaunchPad Venture, Sidecar Fund2, New York Angels, Harvard Business School Alumni Angels of Greater NY, Nobska Point Capital and Alopexx.
CEO
2003 - 2003
Molecular Templates is a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases.
Raised $397,653,924.00 from Sante Ventures, BB Biotech Ventures, Biotechnology Value Fund, Sante Ventures, Biotechnology Value Fund, BB Biotech Ventures and Longitude Capital.